Ibrance
Generic name: Palbociclib
Drug class:
CDK 4/6 inhibitors
Usage of Ibrance
Ibrance is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Ibrance is used in men and women to treat HR-positive, HER2-negative breast cancer that has spread to other parts of the body.
In postmenopausal women, Ibrance is given in combination with a hormonal medicine such as Letrozole (Femara). In others, Ibrance is given together with fulvestrant (Faslodex).
Ibrance side effects
Get emergency medical help if you have signs of an allergic Reaction to Ibrance: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common Ibrance side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Ibrance
You should not use Ibrance if you are allergic to Palbociclib. Tell your doctor if you have signs of infection (such as fever or chills).
To make sure Ibrance is safe for you, tell your doctor if you have ever HAD:
Palbociclib can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
This medicine may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because palbociclib can harm an unborn baby.
You should not breastfeed while using palbociclib and for at least 3 weeks after your last dose.
Relate drugs
- Abemaciclib
- Ibrance
- Kisqali
- Kisqali (200 mg daily-dose)
- Kisqali (400 mg daily-dose)
- Kisqali (600 mg daily-dose)
- Palbociclib
- Ribociclib
- Verzenio
How to use Ibrance
Usual Adult Dose for Breast Cancer:
28-day cycle: 125 mg orally once a day for 21 consecutive days followed by 7 days off Comments: -Administer the recommended dose of an aromatase inhibitor when given with this drug. Refer to the prescribing information for the aromatase inhibitor being used. -When given with this drug, the recommended dose of fulvestrant is 500 mg on Days 1, 15, 29, and once monthly thereafter. Refer to the prescribing Information for fulvestrant. -Pre/perimenopausal women treated with the combination of this drug plus fulvestrant should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to local protocol. Use: For HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women OR fulvestrant in women with disease progression following endocrine therapy.
Warnings
Ibrance affects your lungs or your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, chest pain, shortness of breath, or cough with or without mucus.
What other drugs will affect Ibrance
Other drugs may interact with palbociclib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions